Abstract
Simple SummaryPositron-emission tomography/computed tomography (PET/CT) is used for staging of non-small cell lung cancer (NSCLC) and can help to estimate prognosis in patients treated with immune checkpoint inhibitor (ICI) therapy. Most available data in that field were derived from cohorts treated in higher therapy lines using ICI monotherapy with different drugs. Currently, however, most advanced NSCLC patients receive first-line ICI treatment, often in combination with cytotoxic chemotherapy. We evaluated prognostic PET/CT biomarkers in 85 patients receiving first-line ICI, 70 (82%) of them as a chemotherapy–ICI combination. We found that patients with a higher metabolically active tumor volume (MTV) had a significantly poorer survival and lower radiological response rate. In patients with high MTV, a concomitantly low bone marrow to liver ratio indicated a better prognosis. Our results demonstrate that PET/CT-derived biomarkers can aid therapeutic decision-making in ICI-treated NSCLC.Quantitative biomarkers derived from positron-emission tomography/computed tomography (PET/CT) have been suggested as prognostic variables in immune-checkpoint inhibitor (ICI) treated non-small cell lung cancer (NSCLC). As such, data for first-line ICI therapy and especially for chemotherapy–ICI combinations are still scarce, we retrospectively evaluated baseline 18F-FDG-PET/CT of 85 consecutive patients receiving first-line pembrolizumab with chemotherapy (n = 70) or as monotherapy (n = 15). Maximum and mean standardized uptake value, total metabolic tumor volume (MTV), total lesion glycolysis, bone marrow-/and spleen to liver ratio (BLR/SLR) were calculated. Kaplan–Meier analyses and Cox regression models were used to assess progression-free/overall survival (PFS/OS) and their determinant variables. Median follow-up was 12 months (M; 95% confidence interval 10–14). Multivariate selection for PFS/OS revealed MTV as most relevant PET/CT biomarker (p < 0.001). Median PFS/OS were significantly longer in patients with MTV ≤ 70 mL vs. >70 mL (PFS: 10 M (4–16) vs. 4 M (3–5), p = 0.001; OS: not reached vs. 10 M (5–15), p = 0.004). Disease control rate was 81% vs. 53% for MTV ≤/> 70 mL (p = 0.007). BLR ≤ 1.06 vs. >1.06 was associated with better outcomes (PFS: 8 M (4–13) vs. 4 M (3–6), p = 0.034; OS: 19 M (12-/) vs. 6 M (4–12), p = 0.005). In patients with MTV > 70 mL, concomitant BLR ≤ 1.06 indicated a better prognosis. Higher MTV is associated with inferior PFS/OS in first-line ICI-treated NSCLC, with BLR allowing additional risk stratification.
Highlights
Positron-emission tomography/computed tomography (PET/CT) is widely applied for staging both limited and advanced non-small cell lung cancer (NSCLC) [1,2,3,4]
Several biomarkers derived from PET/CT imaging have been reported to predict outcomes in various malignancies treated with immune-checkpoint inhibitors (ICI) [4,17,18]
Chemotherapy was given for four cycles with no further maintenance therapy, pembrolizumab was continued until progression or toxicity
Summary
Positron-emission tomography/computed tomography (PET/CT) is widely applied for staging both limited and advanced non-small cell lung cancer (NSCLC) [1,2,3,4]. Immune-checkpoint inhibitors (ICI) directed against programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) brought major therapeutic advances in NSCLC. The challenge of predicting favorable responses is still ongoing, whereas biomarkers such as PD-L1 expression, tumor mutational burden, or presence of targetable genetic tumor alterations are being widely applied [14]. Clinical or laboratory parameters such as Eastern Cooperative Oncology Group (ECOG) performance status, neutrophil to lymphocyte ratio, lactate dehydrogenase, or C-reactive protein (CRP). Several biomarkers derived from PET/CT imaging have been reported to predict outcomes in various malignancies treated with ICI [4,17,18]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have